Jean-Marc Huet, Bristol-Myers Squibb
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face.
Jean-Marc Huet
CFO and Executive Vice President, Bristol-Myers Squibb
There is increasing importance of differentiation in the pharmaceutical industry, especially given the political, regulatory, and financial challenges we face. That's why BMS is executing a clear strategy to become a leading biopharma company while remaining focused on operational excellence and strengthening our balance sheet. What is needed now more than ever is the ability to turn challenges into opportunities; we're working to make sure BMS is well positioned to do so.
An innovative environment naturally creates leadership, and provides opportunities for successful, driven people. I make sure that the people whom I work with have what they need in order to be successful. We're all doers here, and that spirit will help us transform into the biopharma company we know we can be.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
